References
- FramptonJEOlanzapine long-acting injection: a review of its use in the treatment of schizophreniaDrugs201070172289231321080745
- DetkeHCMcDonnellDPBrunnerEPost-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of casesBMC Psychiatry2010104320537128
- LuedeckeDSchöttleDKarowALambertMNaberDPost-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and managementCNS Drugs2015291414625424243
- McDonnellDPDetkeHCBergstromRFPost-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanismBMC Psychiatry2010104520537130
- ZypAdhera® (olanzapine) [Summary of Product Characteristics]Indianapolis, INEli Lilly and Company2015
- KaneJMDetkeHCNaberDOlanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophreniaAm J Psychiatry2010167218118920008947
- McDonnellDPLandryJDetkeHCLong-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label studyInt Clin Psychopharmacol201429632233124850228
- American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders4th ed. Text Revision edWashington, DCAmerican Psychiatric Association2000
- KalaliAPatient satisfaction with, and acceptability of, atypical antipsychoticsCurr Med Res Opin199915213513710494497
- NaberDMoritzSLambertMImprovement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugsSchizophr Res2001501–2798811378316
- WareJESnowKKKosinskiMGandekBSF-36 Health Survey Manual and Interpretation GuideBostonThe Health Institute, New England Medical Center1993
- HeinrichsDWHanlonTECarpenterWTJrThe Quality of Life Scale: an instrument for rating the schizophrenic deficit syndromeSchizophr Bull19841033883986474101
- KaySRFiszbeinAOplerLAThe Positive and Negative Syndrome Scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
- GuyWECDEU Assessment Manual for PsychopharmacologyRockville, MDU.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs1976217222
- AnandEBerggrenLDeixCTóthÁMcDonnellDPA 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendationNeuropsychiatr Dis Treat2015111349135726064053
- NaberDOlanzapine pamoate for the treatment of schizophreniaExpert Opin Pharmacother201112462763321254860
- SchöttleDKuhnigkONaberDDrug safety evaluation of olanzapine pamoateExpert Opin Drug Saf201312689790324024627